Lonza, Inc.

VALDOSTA, Ga., April 3, 2023 /PRNewswire/ -- CJB Applied Technologies today announced Brian Sook, Ph.D., has joined the contract chemical development company as Senior Formulation Chemist. Dr. Sook comes to CJB from Arxada, LLC (formerly Lonza Inc.), where he served as Research Project Manager for their crop protection business. Prior to Arxada, Dr. Sook held various roles of increasing responsibilities at Clariant Corporation, Arysta LifeScience, Stepan Company and BioLab, Inc. "We are excited that Brian has joined CJB family, where his knowledge and expertise will strengthen our already robust formulations and product development team," states Jim Loar, Commercial Director, CJB Applied Technologies. "He is yet another investment in our resources dedicated to solving our customer's needs. We look forward to adding more staff and an enhanced lab, analytical and pilot plant capacity and capabilities throughout 2023." Dr. Sook holds a B.A. degree in Chemistry from the University of Kansas and a Ph.D. in Biochemistry from Georgia State University. Dr. Sook and his family are relocating from Cumming, GA, to Valdosta, GA, home of CJB companies. About CJB Applied Technologies, LLC CJB Applied Technologies, LLC is a contract development services company specializing in agricultural and specialty chemicals development projects. Full-service capabilities include consulting, product and process development, formulation, scale-up/pilot plant and packaging. SOURCE CJB Applied Technologies, LLC

DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services. Dr. Kutzer currently serves on Scorpion’s advisory board. Dr. Kutzer brings more than 25 years of experience in the pharmaceutical and biotech industries, building and managing successful contract development and manufacturing organizations. He previously served as President and Chief Executive Officer of Alcami Corporation, a leading provider of development, analytical testing and manufacturing services to the pharmaceutical and biotech industries. Prior to this, he served as President, Divisional CEO and Chief Operating Officer of the Pharma Biotech & Customer Manufacturing division of Lonza Group AG, a multinational manufacturing company for the pharmaceutical and biotechnology sectors, where he had full oversight of the division, which generated over $1.6 billion in annual sales. He also served as a member of the Executive Management Board of Lonza Group AG; President of Lonza Biologics Inc; Chairman of the Board of Directors of Lonza Singapore Inc; Chairman of the Board of Directors of Teva-Lonza TL Biopharmaceuticals AG; Chairman of the Board of Directors of Lonza Biologics plc.; and President and Chairman of Lonza Inc. Dr. Kutzer previously served as an Executive Director on the board of directors for the Drug, Chemical & Associated Technologies Association (DCAT). Dr. Kutzer earned a master’s degree in Chemical and Process Engineering and a Ph.D. in Engineering Sciences from the Technical University of Munich, Germany. Jeff Wolf, CEO of NightHawk and Chairman of Scorpion, commented, “Given the dynamic evolution of Scorpion and rapid progress with construction of our San Antonio and Manhattan, Kansas biomanufacturing facilities, we are delighted to welcome Stephan on board. Throughout his more than 25 years in the biomanufacturing space, Stephan has built and managed several successful contract development and global manufacturing organizations. We tapped Stephan from Scorpion’s advisory board to lead Scorpion through its next phase of growth, and we believe his proven track record will be invaluable to our future success.” Commenting on his appointment, Dr. Kutzer stated, “This is an exciting time at Scorpion as we seek to build a robust and fully integrated CDMO. I am honored to have this opportunity and look forward to supporting Scorpion through this next phase of growth.” About Scorpion Biological ServicesScorpion Biological Services is a contract research, and contract development and manufacturing organization (CDMO) focused on cell- and gene-based therapies and large molecule biologics. Scorpion provides a broad array of clinical-scale biomanufacturing, analytical and R&D services to pharmaceutical and biotech companies from its San Antonio, Texas facilities. Scorpion also plans to offer commercial-scale biomanufacturing from its newly announced site in Manhattan, Kansas. Additional information is available at: https://www.scorpionbio.com/. NightHawk Biosciences, Inc.NightHawk Biosciences is a fully integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization. The Company leverages its integrated ecosystem of subsidiaries to accelerate the development of novel therapies that arm the immune system, breaking through barriers that prolong traditional drug development. This empowers us to bring our ideas to life with efficient control, superior quality, and uncharacteristic agility. For more information on the Company and is subsidiaries, please visit: www.nighthawkbio.com, and also follow us on Twitter. Forward Looking StatementThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as Stephan Kutzer’s proven track record being invaluable to our future success Important factors that could cause actual results to differ materially from current expectations include, among others, the contribution to be made by Stephan Kutzer, the ability to progress the company’s efforts under the NightHawk banner, whether the combined business of NightHawk and Elusys will be successful, NightHawk’s ability to successfully operate as a CDMO, NightHawk’s and its subsidiaries’ ability to maintain license agreements, the continued maintenance and growth of NightHawk’s and its subsidiaries’ patent estates, NightHawk’s product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior results, the ability to initiate clinical trials and if initiated, the ability to complete them on time and achieve the desired results and benefits continuing enrollment as expected, the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to NightHawk’s ability to promote or commercialize its product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of NightHawk’s products, developments by competitors that render such products obsolete or non-competitive, and other factors described in NightHawk’s annual report on Form 10-K for the year ended December 31, 2021, subsequent quarterly reports on Form 10-Qs and any other filings NightHawk makes with the SEC. The information in this presentation is provided only as of the date presented, and NightHawk undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law. Media and Investor Relations ContactDavid Waldman+1 919 289 4017investorrelations@heatbio.com

CALGARY, March 21 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. , a biotechnology company developing a broad pipeline of protein-based pharmaceutical product candidates and non-pharmaceutical products, today announced the publication of new data on the DermaSphere(R) Oleosome Technology by the Company's licensee Lonza Inc. in the leading technology-focused personal care industry trade journal, Cosmetics & Toiletries. The article, entitled "Oleosomes: Natural, Self-emulsifying Systems", which appeared in the January 2006 edition of the journal, discusses for the first time recent research completed by Lonza on the utility of DermaSphere(R) oleosomes as a controlled-release carrier for active ingredients in personal care formulations. "These new results from Lonza independently validate the functionality of our DermaSphere(R) Oleosome Technology as both a self-emulsifying system as well as a carrier and potential delivery mechanism in cosmetic formulations," said Andrew Baum, President and CEO of SemBioSys Genetics Inc. "With Lonza expanding the application development of DermaSphere(R) oleosomes to include these additional benefits, it has increased the market opportunity to SemBioSys for this product, especially considering the marketing and distribution support that an industry leader like Lonza can offer." The article summarizes the unique combination of self-emulsification, anti-oxidation, occlusivity and emolliency benefits of oleosomes as an ingredient system. The article also provides new information describing the flexibility of oleosomes to be loaded with a wide array of oil-soluble materials, enabling its use as a carrier and delivery system for fragrances, vitamins or UV chromophores. The article reports on the remarkable stability of "loaded" oleosomes and provides evidence for controlled release of fragrances in double-blind panel testing. The article concludes that the DermaSphere(R) Oleosome Technology constitutes a true multifunctional ingredient system, providing broad utility for personal care applications. "We are constantly researching and finding new applications for this unique technology," said Carl Cappabianca, Vice President of Global Personal Care Marketing at Lonza. "More formulator benefits are around the corner as we continue our development work with DermaSphere(R) technology." Lonza used the DermaSphere(R) Oleosome Technology developed by SemBioSys to launch its Natrulon(R) OSF in late 2004. Natrulon(R) OSF, the initial product in the line which is comprised of safflower oleosomes, is distributed and supported globally by Lonza. Various upcoming technical conferences and presentations at trade shows, as well as revised advertisements and literature, will further highlight the additional DermaSphere(R) oleosome developments Lonza has discovered. The full article can be viewed by visiting Cosmetics & Toiletries' website at; . About DermaSphere(R) Oleosome Technology The DermaSphere(R) Oleosome Technology was developed by SemBioSys Genetics Inc. Lonza and SemBioSys joined forces in May of 2004 with the execution of a licensing agreement for exclusive global rights to the technology for use in personal care applications. The DermaSphere(R) Oleosome Technology is based on a natural oil-in-water emulsion derived from plant oilseeds. The emulsion is comprised of naturally occurring oil droplets called oleosomes, in which the oil is surrounded by a shell of phospholipids and unique proteins called oleosin. The oleosome core provides emolliency, occlusivity and anti-oxidant effects, and the outer shell provides emulsifying properties. An oleosome emulsion can be used as the entire non-active portion of the oil phase of a typical cosmetic formulation. With this technology cosmetic formulations can be prepared under "cold process" conditions, enabling significant savings in time, energy and inventory management. These unique attributes of the DermaSphere(R) oleosomes allow the technology to be used in a wide range of applications including moisturizing creams, sunscreens, ointments, lotions, eye-care products as well as many others. About SemBioSys Genetics Inc. ( ) Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company focused on the development, commercialization and production of protein-based pharmaceuticals and non-pharmaceutical products based on its plant genetic engineering skills and proprietary oilbody-oleosin technology platform - the Stratosome(TM) Biologics System. Its two lead pharmaceutical product candidates are insulin and a developmental cardiovascular drug called Apo AI. It also has a series of non-pharmaceutical products addressing animal health, nutritional oils and human topical markets. SemBioSys currently has five major funded partnership agreements including agreements with Martek Biosciences Corporation, Lonza Inc. and Arcadia Biosciences, Inc. About Lonza Inc. ( ) Lonza, a chemical and biotechnology company driven by the life sciences, generated sales of CHF 2.52 billion in 2005. Headquartered in Switzerland, Lonza operates 22 production and R&D sites around the world. Its 6300 employees are passionately committed to delivering sustainable value to their customers. Lonza is one of the leading custom manufacturers of chemical intermediates, active ingredients and biopharmaceuticals for the pharmaceutical and agrochemical industries. On the basis of organic chemical, oleochemical and biotechnology platforms, Lonza creates value-added solutions for the nutrition, hygiene & personal care, wood & water treatment and industrial specialty markets. Lonza also offers polymer intermediates, resins and compounds. Lonza is listed on the SWX Swiss Exchange. In the personal care industry, Lonza is one of the world's leading specialty chemical companies with substantial global resources in research and development, technical and applications service and broadly based manufacturing capability. Lonza has an on-going commitment to developing technology and solutions to the personal care industry in a variety of areas including world-leading positions in preservatives and specialty active compounds. Natrulon is a registered trademark of Lonza Inc. DermaSphere and Stratosome are trademarks of SemBioSys Genetics Inc. Except for historical information, this press release may contain forward-looking statements, which are based on the Company's beliefs and assumptions based on information available at the time the assumption was made. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. SemBioSys Genetics Inc. CONTACT: SemBioSys Genetics Inc., Mr. Andrew Baum, President and ChiefExecutive Officer, Phone: (403) 717-8767, Fax: (403) 250-3886, E-mail:bauma@sembiosys.com, Internet: Investor Relations, RossMarshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext. 238), Fax:(416) 815-0080, E-mail: rmarshall@equicomgroup.com; Lonza Inc., Mr. CarlCappabianca, Vice President, Global Personal, Care Marketing, Phone: (201)316-9305, Fax: (201) 785-1364, E-mail: carl.cappabianca@lonza.com,Internet: Lonza Inc., Ms. Christine Casper, CommunicationsManager, Phone: (201) 316-9236, Fax: (201) 785-1364, E-mail:christine.casper@lonza.com, Internet: